Wells Fargo
CRSP icon

Wells Fargo’s CRISPR Therapeutics CRSP Stock Holding History

Wells Fargo’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$5.24K – 7232
2025
Q4 		$5.24K Hold
100
– – ﹤0.01% 6087
2025
Q3 		$6.48K Hold
100
– – ﹤0.01% 6029
2025
Q2 		$4.86K Buy
+100
New +$3.87K ﹤0.01% 6094

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's CRSP Position: Q2 2026 in Review

Wells Fargo reduced its CRISPR Therapeutics (CRSP) stake by 6.2% in Q2 2026, selling an estimated $924K and leaving 263,169 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

Wells Fargo first reported a position in CRSP in Q4 2016 and has held it in 39 quarters since. The position peaked at $75.5M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Wells Fargo held 263,169 shares of CRISPR Therapeutics worth $14.4M as of Q2 2026.
  • Wells Fargo sold 17,540 CRISPR Therapeutics shares in Q2 2026, an estimated $924K.
  • CRISPR Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1900 holding.
  • Wells Fargo first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • Wells Fargo's CRISPR Therapeutics position peaked at $75.5M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.